Bonesupport is planning €60m IPO Swedish orthobiologics company Bonesupport Holding AB announced on Sunday it will go public at Nasdaq Stockholm. more ➔
Targovax raises €21m in private placemen...Norwegian cancer med developer Targovax ASA has doubled its cash and cash equivalents as of 31 December 2016 by raising NOK200m (€21m) in a private placement of new shares. more ➔
Grünenthal in US$300m deal with AstraZene...German Grünenthal Group has entered into an agreement to acquire the global rights to AstraZenecas migraine treatment Zolmitriptan. more ➔
Biocartis launches partnership in liquid b...Belgian liquid biopsy specialist Biocartis Group NV has announced it will co-develop a breast cancer assay with MRC Technology. more ➔
Merck KGaA and F-star in €1bn dealGerman Merck KGaA has secured an option on UKs F-Star Biotechnology Ltds preclinical bispecific PD-L1/LAG checkpoint inhibitor FS118 and four candidates in discovery stage. more ➔
Bicycle raises £40mCambridge-based cancer company Bicycle Therapeutics has raised £40m to advance its clinical pipeline of peptide-based conjugates with antibody-like binding properties. more ➔
EC and EMA provide Brexit guidanceUK-based drug developers and contract manufacturers are set to find partners in the European Economic Area (EEA) to uphold Orphan Drug Designation, MAA or transfer their current UK based site of batch … more ➔
Addex further improves liquidityFollowing a private placement worth CHF3m in February, Swiss allosteric modulator specialist Addex Therapeutics has increased its capital to finance clinical studies of dipraglurant in Parkinsons and … more ➔
AMO Pharma receives FDA Fast Track Status London-based orphan drug developer AMO Pharmas drug AMO-02 has been granted FDA fast track status as treatment for congenital myotonic dystrophy, a sub-indication muscular dystrophy. more ➔
Biocorp partners with VirbacFrench drug delivery specialist Biocorp S.A. (Issoire) has signed an industrialisation contract with Virbac, one of the top-ten vet-med makers. more ➔
